Informace o publikaci

Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock

Autoři	JANTTI T. TARVASMAKI T. HARJOLA V.P. PARISSIS J. PULKKI K. SIONIS A. SILVA-CARDOSO J. KOBER L. BANASZEWSKI M. ŠPINAR Jindřich FUHRMANN V. TOLONEN J. CARUBELLI V. DISOMMA S. MEBAZAA A. LASSUS J.
Rok publikování	2017
Druh	Článek v odborném periodiku
Časopis / Zdroj	American Journal of Cardiology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1016/j.amjcard.2017.06.049
Doi	http://dx.doi.org/10.1016/j.amjcard.2017.06.049
Obor	Kardiovaskulární nemoci včetně kardiochirurgie
Klíčová slova	Cardiogenic Shock
Popis	Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We measured LFTs in 178 patients in CS from serial blood samples taken at 0 hours, 12 hours, and 24 hours. The associations of LFT abnormalities and their early changes with all-cause 90-day mortality were estimated using Fisher's exact test and Cox proportional hazards regression analysis. Baseline alanine aminotransferase (ALT) was abnormal in 58% of the patients, more frequently in nonsurvivors. Abnormalities in other LFTs analyzed (alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin) were not associated with short-term mortality. An increase in ALT of >20% within 24 hours (AALT>+20%) was observed in 24% of patients. AALT>+20% was associated with a more than 2-fold increase in mortality compared with those with stable or decreasing ALT (70% and 28%, p <0.001). Multivariable regression analysis showed that AALT>+20% was associated with increased 90-day mortality independent of other known" risk factors. In conclusion, an increase in ALT in the initial phase was seen in 1/4 of patients in CS and was independently associated with 90-day mortality. This finding suggests that serial ALT measurements should be incorporated in the clinical assessment of patients in CS. (C) 2017 Elsevier Inc. All rights reserved.